Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial

医学 贝伐单抗 奥沙利铂 结直肠癌 人口 随机化 内科学 胃肠病学 氟尿嘧啶 随机对照试验 泌尿科 肿瘤科 外科 化疗 临床终点 癌症 环境卫生
作者
Wentao Tang,Li Ren,Tianshu Liu,Qing‐Hai Ye,Ye Wei,Guodong He,Qi Lin,Xiaoying Wang,Mingliang Wang,Fei Liang,Yuehong Cui,Jianmin Xu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (27): 3175-3184 被引量:126
标识
DOI:10.1200/jco.20.00174
摘要

PURPOSE To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver metastases. METHODS From October 2013 to December 2017, patients with RAS mutant unresectable liver-limited metastases from colorectal cancer were randomly assigned to receive mFOLFOX6 plus bevacizumab (arm A) or mFOLFOX6 alone (arm B). The resectability of liver metastases was determined by a local multidisciplinary team. The primary end point was the actual rate of patients converted to R0 resection for liver metastases. Secondary end points included tumor response, survival, and toxicity. The block randomization method was used. RESULTS The intention-to-treat population comprised 241 patients. A total of 121 patients were randomly assigned to arm A and 120 to arm B. The median follow-up time was 37.0 months for all patients. The R0 resection rates for liver metastases were 22.3% (27 of 121 patients) in arm A and 5.8% (7 of 120 patients) in arm B, with a significant difference ( P < .01). Patients in arm A had significantly better objective response rates (54.5% v 36.7%; P < .01), median progression-free survival (9.5 v 5.6 months; P < .01) and median overall survival (25.7 v 20.5 months; P = .03) compared with those in arm B. The addition of bevacizumab was associated with more frequent proteinuria (9.9% v 3.3%; P = .04) and hypertension (8.3% v 2.5%; P < .05). CONCLUSION For patients with initially unresectable RAS mutant colorectal liver metastases, bevacizumab combined with mFOLFOX6 increased the resectability of liver metastases and improved response rates and survival compared with mFOLFOX6 alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
TYH关闭了TYH的文献求助
1秒前
1秒前
跳跃靖发布了新的文献求助10
1秒前
2秒前
CipherSage的应助被朴素的士晋采纳,获得10
2秒前
molihuakai的应助被阳光雨堂采纳,获得10
2秒前
搞怪的芙发布了新的文献求助10
3秒前
慕青的应助被YH采纳,获得10
3秒前
yu完成签到,获得积分20
4秒前
4秒前
星辰大海的应助被WYL采纳,获得10
4秒前
5秒前
哈基米完成签到,获得积分10
5秒前
5秒前
6秒前
Hasson发布了新的文献求助10
6秒前
十一完成签到,获得积分10
6秒前
6秒前
drugster完成签到,获得积分10
6秒前
SciGPT的应助被heoouijee采纳,获得10
6秒前
112233完成签到,获得积分10
7秒前
桐桐的应助被香橙采纳,获得10
7秒前
所所的应助被流年采纳,获得10
7秒前
852的应助被务实的书芹采纳,获得10
7秒前
8秒前
CarryLJR发布了新的文献求助10
8秒前
研友_VZG7GZ的应助被flamez采纳,获得10
8秒前
天天快乐的应助被靓丽芙蓉采纳,获得10
8秒前
9秒前
9秒前
9秒前
zzzzz完成签到,获得积分10
9秒前
xgx984完成签到,获得积分10
9秒前
一杯芝士发布了新的文献求助10
9秒前
9秒前
Zero发布了新的文献求助10
9秒前
哈基米发布了新的文献求助10
9秒前
sss的应助被drizzle采纳,获得10
10秒前
专一的飞莲完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417